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Introduction
Prosthetic joint infections (PJI) are one of the most
complication of joint replacement surgery and report a
considerable disability and cost. This complication occurs
in 0.8-1.9% of knee prostheses (TKA) and 0.3-1.7% of hip
replacement (THA) [1]. These percentages may be
underestimated because of the ability of some bacteria to
grow in community of aggregation on the surface of the
prosthesis, defined biofilm, which makes difficult their
isolation by standard culture tests. In fact, in a significant
percentage of prosthetic infections, the responsible agent
remains unknown, and this may affect the outcome [2,3].
The classification of implant-associated infections is
related to the onset of symptoms after implantation.
Early infection is defined as appearance of the first signs
and symptoms of infection during the first 3 months
after surgery. However, some authors limit these surgical
site infection to the first 4- weeks [4]. Delayed manifesta-
tion is defined as an infection in which the first signs and
symptons appear between 3months and 2 years post-sur-
gery, and late manifestation is defined as the appearance
of first signs and symptons of infection > 2 years post-
surgery. Each type has specific etiopathogenic properties
that influence the therapeutic options. Outcome data on
treatment are limited. Aim of this study was to evaluate
the characteristics of patients with PJI and their outcome
after treatment.
Methods
In an observational study we included the cases of PJI
referred to our Department during the last 3 years. The
presence of at least one of the following findings confirm
the infection [5]: I) two or more cultures of joint aspirates
or cultures of intraoperative specimens yielding the same
microorganism; II) purulence surrounding the prosthesis
at the time of explantation; III) acute inflammation
detected on histopathological examination of peropros-
thetic issue; IV) a sinus tract that communicated with the
prosthesis. Cure was defined by clinical, microbiologic
and laboratory (normalization of erythrocyte sedimenta-
tion rate and C-reactive protein level) evidences and, as
assessed 6 months after the end of therapy.
Results
Twenty-two cases of PJI (median age 65 years), were
observed (10 THA, 12 TKA). Co-morbidity were
reported in 12 (54%) patients, diabetes mellitus, cardio-
vascular co-morbidities, and chronic liver disease were
retrieved more frequently. Eight cases were observed
within 3 months from surgical procedure (early infec-
tion), and 13 cases were observed after >3 months
(delayed infections). Early infections ware caused by
Staphylococcus aureus in six patients (2 methicillin
resistant), in one patient we detected Pseudomonas aer-
uginosa and no microbiologic evidence was reported in
one case. All early infections received debridement and
retention of prosthesis followed by antibiotic therapy
(success rate 75%). Delayed infections were caused by
coagulase negative Staphylococci in 10 patients, in three
patients no microbiologic evidence was reported.
Delayed infections were treated with a two-stage
exchange in 11 cases (success rate 85%). The remaining
2 cases received long-term suppressive antibiotic treat-
ment without prosthetic joint replacement, because of
refusal of further surgical procedure or because of co-
morbidity.
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Conclusion
Prosthetic joint infections are frequently sustained by
multi-drug resistant bacteria. Debridement followed
by antibiotic treatment is a successful procedure for
early infection. Satisfactory outcomes can be obtained
also with two-stage revision. Patients with delayed infec-
tions have to be evaluated on the basis of underlying
conditions to establish the surgical and antimicrobial
approaches.
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